Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder
- PMID: 26622319
- PMCID: PMC4647142
- DOI: 10.1177/1756287215603274
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder
Abstract
Clinical trials have shown that hexaminolevulinate (HAL) fluorescence cystoscopy improves the detection of bladder tumors compared with standard white-light cystoscopy, resulting in more efficacious treatment. However, some recent meta-analyses report controversially on recurrence-free rates with this procedure. A systematic review of literature was performed from December 2014 to January 2015 using the PubMed, Embase and Cochrane databases for controlled trials on photodynamic diagnosis (PDD) with HAL. A total of 154 publications were found up to January 2015. Three of the authors separately reviewed the records to evaluate eligibility and methodological quality of clinical trials. A total of 16 publications were considered eligible for analysis. HAL-PDD-guided cystoscopy increased overall tumor detection rate (proportion difference 19%, 95% confidence interval [CI] 0.152-0.236) although the benefit was particularly significant in patients with carcinoma in situ (CIS) lesion (proportion difference 15.7%, 95% CI 0.069-0.245) and was reduced in papillary lesions (Ta proportion difference 5.9%, 95% CI 0.014-0.103 and T1 proportion difference 1.2%, 95% CI 0.033-0.057). Moreover, there were 15% of patients (95% CI 0.098-0.211) with at least one additional tumor seen with PDD. With regard to recurrence rates, the data sample was insufficient for a statistical analysis, although the evaluation of raw data showed a trend in favor of HAL-PDD. This meta-analysis confirms the increased tumor detection rate by HAL-PDD with a most pronounced benefit for CIS lesion.
Keywords: bladder cancer; hexaminolevulinate; meta-analysis; photodynamic diagnosis; tumor detection.
Conflict of interest statement
Figures


Similar articles
-
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.Eur Urol. 2013 Nov;64(5):846-54. doi: 10.1016/j.eururo.2013.03.059. Epub 2013 Apr 8. Eur Urol. 2013. PMID: 23602406 Review.
-
Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.Photobiomodul Photomed Laser Surg. 2019 Sep;37(9):551-558. doi: 10.1089/photob.2019.4634. Epub 2019 Jul 24. Photobiomodul Photomed Laser Surg. 2019. PMID: 31339825
-
Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.J Endourol. 2009 Jun;23(6):983-8. doi: 10.1089/end.2008.0642. J Endourol. 2009. PMID: 19441882 Clinical Trial.
-
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.J Urol. 2007 Jul;178(1):62-7. doi: 10.1016/j.juro.2007.03.034. Epub 2007 May 11. J Urol. 2007. PMID: 17499283 Clinical Trial.
-
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4. Eur Urol. 2014. PMID: 25001887 Review.
Cited by
-
Photodynamic Therapy for Bladder Cancers, A Focused Review†.Photochem Photobiol. 2023 Mar;99(2):420-436. doi: 10.1111/php.13726. Epub 2022 Oct 14. Photochem Photobiol. 2023. PMID: 36138552 Free PMC article. Review.
-
Photodynamic Therapy: A Novel Approach for Head and Neck Cancer Treatment with Focusing on Oral Cavity.Biol Proced Online. 2024 Aug 17;26(1):25. doi: 10.1186/s12575-024-00252-3. Biol Proced Online. 2024. PMID: 39154015 Free PMC article. Review.
-
Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy.Lasers Med Sci. 2022 Mar;37(2):1155-1166. doi: 10.1007/s10103-021-03367-1. Epub 2021 Jul 4. Lasers Med Sci. 2022. PMID: 34218351 Free PMC article.
-
Bactericidal activity of esculetin is associated with impaired cell wall synthesis by targeting glutamate racemase of Neisseria gonorrhoeae.Mol Divers. 2024 Oct;28(5):3181-3198. doi: 10.1007/s11030-023-10745-0. Epub 2023 Oct 25. Mol Divers. 2024. PMID: 37880544
-
The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.Curr Urol Rep. 2017 May;18(5):39. doi: 10.1007/s11934-017-0685-8. Curr Urol Rep. 2017. PMID: 28324275 Review.
References
-
- Babjuk M., Burger M., Zigeuner R., Shariat S., van Rhijn B., Compérat E., et al. (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64: 639–653. - PubMed
-
- Burguèsa J., Condeb G., Olivac J., Abascald I., Iborrae M., Puertasf F., et al. (2011) Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group [in Spanish]. Actas Urol Esp 35: 439–445. - PubMed
-
- Cauberg E., Kloen S., Visser M., de la Rosette J., Babjuk M., Soukup V., et al. (2010) Narrow band imaging cystoscopy improves detection of non-muscle-invasive bladder cancer. Urology 76: 658–663. - PubMed
-
- Cicchi R., Crisci A., Cosci A., Nesi G., Kapsokalyvas D., Giancane S., et al. (2010) Time- and Spectral-resolved two-photon imaging of healthy bladder mucosa and carcinoma in situ. Opt Express 18: 3840–3849. - PubMed
-
- Dindyal S., Nitkunan T., Bunce C. (2008) The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 5: 153–158. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources